D-4F enhances sevoflurane-induced vascular protection during acute hyperglycemia

Abstract

Abstract:

AIM: To investigate the effects of sevoflurane-induced vascular protection by apolipoprotein A-1 mimetic D-4F during acute hyperglycemia. METHODS:Thrty-two male C57BL/6J mice were randomly assigned to 4 groups (n=8). Control group(CON group), D-4Fgroup, acute hyperglycemia group(AHG group), dextrose 2 g/kg (intraperitoneal injection); AHG+D-4F group. Blood glucose, isometric aortic tension, nitric oxide (NO) were measured in mice in the absence or presence of sevoflurane（1.71%）. Expressions of eNOS，p-eNOS，Cav-1 in arterioles were determined by Western blot.Superoxide generation species (ROS) were assessed in human umbilical vein endothelial cells (HUVEC) cultured in 5.5 or 20.0 mmol/L glucose with isoflurane (0.5 mmol/L) in the presence or absence of brefeldin A (BFA, 4 μg/mL) or D-4F (0.5 μg/mL). RESULTS: Vasodilation, phosphorylations, NO production of eNOS were decreased while Cav-1 expression was increased during acute hyperglycemia. D-4F increased endothelium-dependent vasodilation (P<0.01) while decreased Cav-1 expression and ROS production in HG+D-4F group after sevoflurane-induction.CONCLUSION: Polipoprotein A-1 mimetic D-4F can enhance sevoflurane-induced vascular protection, decrease Cav-1 expression and ROS production while increase NO production during acute hyperglycemia.

Key words: sevoflurane, vascular protection, D-4F, acute hyperglycemia, NO, ROS

CLC Number:

R965.2

LIU Ruohai, LU Yuanyuan, LI Liling, SHEN Lulu, CAO Hong, LI Jun, LI Xu. D-4F enhances sevoflurane-induced vascular protection during acute hyperglycemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 743-748.

References

［1］Ishihara M, Inoue I, Kawagoe T, et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction［J］.Am Heart J, 2003, 146(4):674-678.
［2］Lohr N, Kersten JR. Man overboard! Rescuing myocardium with membrane rafts［J］. Anesthesiology, 2010, 112(5):1076-1078.
［3］Amour J, Brzezinska AK, Jager Z, et al. Hyperglycemia adversely modulates endothelial nitric oxide synthase during anesthetic preconditioning through tetrahydrobiopterin- and heat shock protein 90-mediated mechanisms［J］. Anesthesiology, 2010, 112(3):576-585.
［4］Tsutsumi YM, Kawaraguchi Y, Horikawa YT, et al. Role of caveolin-3 and glucose transporter-4 in isoflurane-induced delayed cardiac protection ［J］. Anesthesiology, 2010, 112(5):1136-1145.
［5］Ou J, Wang J, Xu H, et al. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet［J］. Circ Res, 2005, 97(11):1190-1197.
［6］Baotic I, Ge ZD, Sedlic F, et al. Apolipoprotein A-1 mimetic D-4F enhances isoflurane-induced eNOS signaling and cardioprotection during acute hyperglycemia［J］. Am J Physiol Heart Circ Physiol, 2013,305(2):H219-227.
［7］丁云录，成光宇，朱光泽,等. 消渴脂平胶囊治疗2 型糖尿病高脂血症实验研究［J］. 长春中医药大学学报, 2016 , 32(4):692-694.
［8］Sviridov D, Fidge N, Beaumier-Gallon G, et al. Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae)［J］. Biochem J, 2001, 358(Pt 1):79-86.
［9］Cohen AW, Combs TP, Scherer PE, et al. Role of caveolin and caveolae in insulin signaling and diabetes［J］. Am J Physiol Endocrinol Metab, 2003, 285(6):E1151-1160.
［10］Patel HH, Tsutsumi YM, Head BP, et al. Mechanisms of cardiac protection from ischemia/reperfusion injury: a role for caveolae and caveolin-1［J］. FASEB J, 2007, 21(7):1565-1574.
［11］Li X, Xing W, Wang Y, et al. Upregulation of caveolin-1 contributes to aggravated high-salt diet-induced endothelial dysfunction and hypertension in type 1 diabetic rats［J］. Life Sci , 2014, 113(1-2):31-39.
［12］Cassuto J, Dou H, Czikora I, et al. Peroxynitrite disrupts endothelial caveolae leading to eNOS uncoupling and diminished flow-mediated dilation in coronary arterioles of diabetic patients［J］. Diabetes, 2014, 63:1381-1393.
［13］Pojoga LH, Yao TM, Opsasnick LA,et al. Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice［J］. J Pharmacol Exp Ther, 2014, 348:260-270.
［14］Peterson SJ, Kim DH, Li M,et al. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice［J］. J Lipid Res, 2009, 50(7):1293-1304.
［15］Wool GD, Reardon CA, Getz GS. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties［J］. J Lipid Res, 2008, 49(6):1268-1283.
［16］Bloedon LT, Dunbar R, Duffy D, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients［J］. J Lipid Res, 2008, 49(6):1344-1352.
［17］Van den Brom CE, Boly CA, Bulte CS, et al. Myocardial perfusion and function are distinctly altered by sevoflurane snesthesia in diet-induced prediabetic rats［J］. J Diabetes Res, 2016;2016:5205631. doi: 10.1155/2016/5205631. Epub 2015 Dec 28.
［18］Yassine HN, Jackson AM, Reaven PD, et al. The application of multiple reaction monitoring to assess apo A-I methionine oxidations in diabetesand cardiovascular disease［J］.Transl Proteom, 2014,1(4/5):18-24.
［19］Khandouzi N, Shidfar F, Rajab A, et al. The effects of ginger on fasting blood sugar, hemoglobin a1c,apolipoprotein B,apolipoprotein a-I and malondialdehyde in type 2 diabetic patients［J］.Iran J Pharm Res, 2015,14(1):131-140.
［20］Ou Z, Ou J, Ackerman AW,et al. L-4F, an apolipoprotein A-1 mimetic, restores nitric oxide and superoxide anion balance in low-density lipoprotein-treated endothelial cells［J］. Circulation,2003,107(11):1520-1524.

[1]	DU Caifeng, MAO Yunan, GAO Jia, WANG Juan, LI Xiaoye, TIAN Junsheng, LIU Hongqi. Research on serum metabolic markers of menopausal syndrome based on 1H-NMR metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 961-968.
[2]	LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin. Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
[3]	WANG Jingang, LI Qiang, SUN Huiyan, WANG Hongquan. Recent progress in understanding the neuroprotective mechanism of carnosic acid in Parkinson's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1073-1080.
[4]	HE Lihua, ZHU Xiuzhi, JIANG Yizhou. Research progress on immunotherapy for triple-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
[5]	FU Xiaoyu, KONG Deguang, LI Juanjuan. Treatment progress of triple positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
[6]	WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan. Research progress on diagnosis and treatment of granulomatous lobular mastitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
[7]	WANG Kun, XU Peipei, ZHOU Lanlan, LU Sheng. Mechanism of neuroprotective effect of ginsenoside Rg1 regulating Epac1/Rap1 signaling pathway in rats with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 721-727.
[8]	LI Shixu, LI Linyun, WANG Xin, LI Ke, BIAN Hua. Effects of Ginkgo biloba extract on renal injury in rats with experimental renal failure through miR-145/FOXO1 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 728-735.
[9]	FAN Jie, JIN Yongming, JIANG Xiaolong, JIANG Guohua. Molecular mechanism of lncRNA HOTAIR regulating miR-206 on the proliferation and apoptosis of rheumatoid arthritis synovial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 736-742.
[10]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[11]	HOU Qiong, LIU Fei, CHEN Chuanrong. Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
[12]	LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin. The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
[13]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[14]	WANG Donghui, JIANG Suwen, HU Airong, ZHU Bo, HE Zheyun, ZHANG Lukan, WANG Jialan, FAN Ying, LIN Ken . Mulberry exerts antioxidant stress effect in rats with nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 609-616.
[15]	XIE Jingjing, YIN Hongtao, LIU Jinjin, SUN Weiming, ZHEN Donghu. Baseline serum 25-hydroxyvitamin D3 levels and risk of metabolic syndrome: a prospective cohort study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 641-652.